Eliem Therapeutics Inc (ELYM) Peer Comparison
$3.09
$-0.14
(-4.33%)
As on 04-Dec-2024 09:30EDT
Market cap
$343 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Edit
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
343 | 16,765 | 16,261 | 13,492 | 12,332 |
Revenue ($ Mln) |
-- | 2,782 | 1,054 | 2,436 | 1,284 |
Net Profit ($ Mln) |
-64.20 | 491.50 | 755.85 | 860.62 | -325.10 |
Net Margin (%) |
-- | 17.67 | 71.69 | 35.33 | -25.32 |
RoE (%) |
-38.92 | 110.09 | -- | 42.98 | -57.72 |
Price to Earnings |
-- | 35.25 | 19.00 | 17.40 | -- |
Price-To-Book |
0.97 | 39.29 | 9.76 | 7.42 | 23.98 |
Income Statement ($ Mln)
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 1,885.84 | 266.72 | 1,830.21 | 0.00 |
|
Cost of Revenue
|
0.00 | 1,361.34 | 44.40 | 72.55 | 0.53 |
|
Gross Profit
|
-- | 524.51 | 222.32 | 1,757.66 | 0.00 |
|
Operating Expenses
|
17.84 | 187.68 | 677.86 | 1,586.78 | 380.50 |
|
Operating Profit (EBIT)
|
-17.84 | 336.83 | -455.54 | 170.89 | -380.50 |
|
Other Income
|
0.00 | 7.07 | -- | -0.20 | 2.19 |
|
Profit before Tax
|
-64.20 | 335.68 | -474.14 | 257.52 | -373.63 |
|
Provision for Tax
|
-3.01 | 52.87 | 7.30 | 49.76 | 3.96 |
|
Profit after Tax (Net Income)
|
-64.20 | 282.81 | -481.45 | 207.77 | -373.63 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
0.00 | 245.37 | -583.19 | 182.28 | -295.35 |
Liabilities ($ Mln)
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
222.28 | 558.95 | -145.70 | 2,263.91 | 405.33 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | 172.75 | 234.78 | 284.17 | 116.67 |
|
Current Liabilities
|
3.74 | 925.13 | 736.51 | 394.28 | 118.55 |
|
Total Liabilities
|
110.47 | 1,656.83 | 825.59 | 2,942.36 | 640.55 |
Assets ($ Mln)
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.02 | 1,063.00 | 122.87 | 1,624.40 | 3.27 |
|
Current Assets
|
226.00 | 593.83 | 702.72 | 1,317.96 | 637.28 |
|
Total Assets
|
110.47 | 1,656.83 | 825.59 | 2,942.36 | 640.55 |
|
Total Debt*
|
0.10 | 142.12 | 743.06 | 189.94 | 117.19 |
|
Net Current Assets
|
222.26 | -331.30 | 505.38 | 923.68 | 518.73 |
Cashflow ($ Mln)
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-20.60 | 433.37 | -467.36 | 333.32 | -324.23 |
|
Cash Flow from Investing Activities
|
-- | -34.63 | 286.47 | -26.96 | -502.52 |
|
Cash from Financing Activities
|
0.84 | -182.64 | 134.29 | -546.05 | 595.12 |
|
Net Cash Inflow / Outflow
|
-- | -426.47 | -- | -161.21 | 295.28 |
Ratios
Profitability Ratios
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-29.62 | 44.32 | -65.14 | 8.10 | -97.07 |
|
ROE (%)
|
-38.92 | 59.83 | -818.43 | 8.74 | -123.98 |
|
ROA (%)
|
-36.72 | 18.80 | -50.27 | 6.91 | -74.49 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 15.00 | -180.51 | 11.35 | -13,517.16 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.29 | 4.21 | 0.14 | -- |
|
EBIT Growth (%)
|
57.20 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-49.47 | 15.26 | 17.45 | 13.98 | -26.50 |
|
EPS Growth (%)
|
-- | 0.17 | 0.18 | 0.18 | -0.10 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 34.49 | -14.81 | 36.14 | -12.24 |
|
Price / Book Value
|
-- | 17.45 | -48.94 | 3.32 | 11.28 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
7.80 | 26.63 | -18.18 | 23.67 | -11.25 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.25 | -5.10 | 0.08 | 0.29 |
|
Short term debt to equity ratio
|
0.00 | 0.52 | -2.99 | 0.01 | 0.00 |
|
Current Ratio
|
60.41 | 0.64 | 0.95 | 3.34 | 5.38 |
|
Quick Ratio
|
60.41 | 0.64 | 0.67 | 3.30 | 5.38 |
|
Interest Coverage
|
-26.96 | 688.87 | -9.76 | 3.75 | -28.39 |
Operating Efficiency Ratios
| Eliem Therapeutics Inc (ELYM) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 15.82 | 13.45 | 12.97 | -- |
|
Asset Turnover
|
0.00 | 1.25 | 0.28 | 0.61 | 0.00 |
|
Receivable days
|
-- | 53.44 | 32.72 | 45.12 | -- |
|
Inventory Days
|
-- | 0.00 | 1,397.01 | 127.43 | 0.00 |
|
Payable days
|
-- | 8.71 | 804.62 | 167.24 | 17,975.57 |
|
Cash Conversion Cycle
|
-- | 44.73 | 625.11 | 5.31 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
